Posted by Michael Wonder on 24 Jul 2019
FDA approves first treatment for severe hypoglycaemia that can be administered without an injection
24 July 2019 - The U.S. FDA today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycaemia that can be administered without an injection.
Injectable glucagon has been approved for use in the U.S. for several decades.The efficacy and safety of Baqsimi nasal powder glucagon to treat severe hypoglycaemia was evaluated in two studies of 83 and 70 adults with diabetes, comparing a single dose of Baqsimi to a single dose of glucagon injection in causing a blood sugar response to insulin-induced hypoglycaemia. Baqsimi adequately increased blood sugar levels. In a paediatric study of 48 patients over the age of four with type 1 diabetes, similar results were observed.
